QBT 006
Alternative Names: QBT-006Latest Information Update: 01 Mar 2022
At a glance
- Originator Qing Bile Therapeutics
- Class Bile acids and salts; Hepatoprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Intrahepatic cholestasis; Non-alcoholic steatohepatitis; Primary sclerosing cholangitis
Most Recent Events
- 25 Feb 2022 Preclinical trials in Intrahepatic cholestasis in Canada (unspecified route) before Febuary 2022 (Qing Bile therapeutics' pipeline, February 2022)
- 25 Feb 2022 Preclinical trials in Non-alcoholic steatohepatitis in Canada (unspecified route) before Febuary 2022 (Qing Bile therapeutics' pipeline, February 2022)
- 25 Feb 2022 Preclinical trials in Primary sclerosing cholangitis in Canada (unspecified route) before Febuary 2022 (Qing Bile therapeutics' pipeline, February 2022)